News
ZLDPY
9.31
NaN%
--
Zealand Pharma tumbles 24% as weight-loss drug data sparks safety fears
Seeking Alpha · 06/08 10:27
Zealand phase 2 data on petrelintide shows durable weight loss
Seeking Alpha · 06/05 21:42
Weekly Report: what happened at ZLDPY last week (0908-0912)?
Weekly Report · 09/15/2025 12:35
Weekly Report: what happened at ZLDPY last week (0901-0905)?
Weekly Report · 09/08/2025 12:37
Weekly Report: what happened at ZLDPY last week (0825-0829)?
Weekly Report · 09/01/2025 12:29
Weekly Report: what happened at ZLDPY last week (0818-0822)?
Weekly Report · 08/25/2025 12:48
Weekly Report: what happened at ZLDPY last week (0811-0815)?
Weekly Report · 08/18/2025 12:34
Weekly Report: what happened at ZLDPY last week (0804-0808)?
Weekly Report · 08/11/2025 12:48
Weekly Report: what happened at ZLDPY last week (0728-0801)?
Weekly Report · 08/04/2025 12:50
More
Webull provides a variety of real-time ZLDPY stock news. You can receive the latest news about ZEALAND PHAR A through multiple platforms. This information may help you make smarter investment decisions.
About ZLDPY
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.